G

Glenmark Life Sciences Ltd
NSE:GLS

Watchlist Manager
Glenmark Life Sciences Ltd
NSE:GLS
Watchlist
Price: 1 045.65 INR -3.19% Market Closed
Market Cap: 128.1B INR
Have any thoughts about
Glenmark Life Sciences Ltd?
Write Note

Glenmark Life Sciences Ltd
Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Glenmark Life Sciences Ltd
Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
G
Glenmark Life Sciences Ltd
NSE:GLS
Common Stock
â‚ą245.1m
CAGR 3-Years
132%
CAGR 5-Years
66%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Common Stock
â‚ą834m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Common Stock
â‚ą1.6B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Common Stock
â‚ą2.4B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
1%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Common Stock
â‚ą1.7B
CAGR 3-Years
26%
CAGR 5-Years
15%
CAGR 10-Years
7%
M
Mankind Pharma Ltd
NSE:MANKIND
Common Stock
â‚ą400.6m
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Glenmark Life Sciences Ltd
Glance View

Market Cap
128.1B INR
Industry
Pharmaceuticals

Glenmark Life Sciences Ltd. engages in the development and manufacture of non-commoditized active pharmaceutical ingredients. The company is headquartered in Solapur, Maharashtra. The company went IPO on 2021-08-06. The Company’s product portfolio comprises of various therapeutic segments, which include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, gastrointestinal health, oncology, pain management and anti-infectives. Its products include Adapalene, Alogliptin Benzoate, Amiodarone HCl, Esomeprazole Sodium, Eszopiclone, Etoricoxib, Omeprazole, Oxcarbazepine, Zolpidem Tartrate, Zonisamide and Voriconazole. The Company’s products also include Vildagliptin, Aprepitant, Bosentan, Cilostazol, Deferasirox, Fluconazole, Ivacaftor, Pirfenidone, Riluzole, Sucralfate, Ticagrelor, Telmisartan and Umifenovir. The Company’s research and development facilities are located at Mahape, Ankleshwar and Dahej in India and manufacturing facilities are located at Ankleshwar, Dahej, Mohol and Kurkumbh.

GLS Intrinsic Value
715.71 INR
Overvaluation 32%
Intrinsic Value
Price
G

See Also

What is Glenmark Life Sciences Ltd's Common Stock?
Common Stock
245.1m INR

Based on the financial report for Mar 31, 2024, Glenmark Life Sciences Ltd's Common Stock amounts to 245.1m INR.

What is Glenmark Life Sciences Ltd's Common Stock growth rate?
Common Stock CAGR 5Y
66%

Over the last year, the Common Stock growth was 0%. The average annual Common Stock growth rates for Glenmark Life Sciences Ltd have been 132% over the past three years , 66% over the past five years .

Back to Top